About KalVista Pharmaceuticals, Inc.
KalVista is a global pharmaceutical company dedicated to delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. The KalVista team discovered and developed EKTERLY®—the first and only oral on-demand treatment for hereditary angioedema (HAE)—and continues to work closely with the global HAE community to improve treatment and care for this disease around the world.
For more information about KalVista, please visit www.kalvista.com and follow us on LinkedIn, X, Facebook and Instagram.
ABOUT THE ROLE
The Senior National Account Director (NAD) will play an important role in the growth of KalVista and its transformation into a fully integrated biotechnology organization by enabling patient access to KalVista innovative products. This role is a US field-based position and is responsible for developing and leveraging relationships with PBM’s, National and Regional plans and for both managed and state Medicaid plans to secure and grow access for KalVista products. The National Account Director will report directly to the Executive Director, Payer Account Management.
RESPONSIBILITIES
- Establish relationships with Pharmacy and Medical teams responsible for creating pharmacy and medical policies
- Deliver Value proposition and Health Economic information to educate payers and the formulary committees
- Create account plans to quickly maximize access and reimbursement with KalVista products
- Collaborate with medical, advocacy and sales teams to remove access barriers for launch
QUALIFICATIONS
- Minimum 10 years field-based biotech/ pharmaceutical experience with at least 5 years of managed care experience. National Accounts experience preferred
- Rare, Orphan, cell, gene, specialty experience preferred
- Bachelor’s degree required. Master’s advanced degree preferred
- Exceptional communication skills and presentation abilities
- Strategic thinking required
- Experience impacting medical and pharmacy policy
- Ability to travel greater than 50%
- Self-motivated
OUR VISION
We Deliver Novel Therapies That Empower People To Live Better Lives.
Our OPERATING PRINCIPLES, referenced below, guide our behaviors and decisions:
Define Success – And Then Deliver
Act with outcomes in mind. Have high expectations. Details Matter.
Be Data Driven And Openly Debate – But Be Decisive
Time is valuable. Say the thing you can’t say. Understand timelines and meet them.
Have An Ownership Mentality
This is your company; treat it that way. Protect our resources, reputation, and results.
Be Internally Collaborative And Externally Competitive
We go further, faster, together. Have a bias for action, but bring others along. Offer solutions, not just problems.
Good People = Great Company
Act with integrity. Assume positive intent. Be Kind.
Important Notice to Third-Party Recruiters & Staffing Agencies:
The current job openings advertised on this website are for the sole purpose of candidates to apply directly. Unsolicited and anonymous CVs submitted in any manner to KalVista employees, including to employee personal e-mail accounts, are considered to be the property of KalVista and will not qualify for a fee to be paid. Referral fees will only be payable where KalVista has agreed with an agency to work on a specific appointment, and then only in conjunction with a fully-executed contract for service.
If any Agency representative contacts a KalVista Hiring Manager or company employee, other than a member of the KalVista Talent Acquisition team, to solicit an appointment to engage on a job opening, that Agency will not be considered for that specific job opening or future opportunities with KalVista.
Thank you for your understanding and cooperation.
Similar Jobs
What We Do
For nearly a decade, KalVista Pharmaceuticals has been focused on addressing the critical unmet needs of those living with hereditary angioedema (HAE). With more than 250 employees worldwide, we leverage our team’s vast knowledge and expertise across all aspects of research, development, and commercialization to redefine the future of HAE treatment and advance global care for those who need it most.

.png)




